



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Road,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

EOFY 2022 Information

Melbourne, 11 August 2022: Infectious disease therapy and vaccine development company BioDiem Ltd and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following update.

Live attenuated flu virus (LAIV) vaccine licensee progress in China

China-based Changchun BCHT Biotechnology Co (BCHT) holds an exclusive licence from BioDiem for the vaccine technology based on the live attenuated influenza virus (LAIV). BCHT’s licence covers the private sector market in China for pandemic and seasonal influenza vaccines made using an egg-based production method.

BCHT holds a complementary licence to the LAIV for the public market in China via a sublicense from the World Health Organisation. BioDiem received a payment from BCHT of US\$227,176 in March 2022.

Opal Biosciences Ltd (“Opal”)

Opal’s strategic focus has been re-directed towards growing Australia’s vaccine and pharmaceutical manufacturing capability. Commercial opportunities are in discussion and last month Opal submitted an application for \$5m to the federal government’s Medical Research Future Fund’s mRNA Clinical Trial Enabling Infrastructure grant program. Additional applications are also in progress and discussions with state governments underway.

EOFY Share Price information

The EOFY 2022 share price information is as follows being the last sale price:

- BioDiem ordinary shares = \$0.08 (8 cents)
- BioDiem preference shares = \$0.08 (8 cents)

For those BioDiem shareholders who also separately hold shares in Opal, the EOFY 2022 share price of Opal Biosciences ordinary shares is \$0.075 (7.5 cents).

Shareholder Information at Share Registry, Computershare.

Shareholders are asked to ensure their contact details/email addresses are up-to-date at Computershare. This can be done online via the Computershare Investor Centre (www.computershare.com.au).

- ENDS -

Further information

Julie Phillips, Chief Executive Officer, BioDiem Ltd

Phone +61 3 9692 7222

Email jphillips@biodiem.com

Twitter @biodiem @opalbiosciences